Adaptimmune Therapeutics Faces Delisting Concerns

TL;DR

Adaptimmune's on the chopping block - might get delisted.

AI Summary

Adaptimmune Therapeutics PLC filed an 8-K on September 12, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, incorporated in England and Wales, is based in Abingdon, Oxfordshire. This filing indicates potential issues with the company's continued listing on a stock exchange.

Why It Matters

This filing signals potential financial distress or non-compliance with exchange rules, which could significantly impact investor confidence and the stock's liquidity.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to trade publicly, posing a significant risk to investors.

Key Players & Entities

• Adaptimmune Therapeutics PLC (company) — Registrant
• September 11, 2025 (date) — Earliest event reported
• September 12, 2025 (date) — Date of report
• England and Wales (jurisdiction) — Place of incorporation
• Abingdon, Oxfordshire (location) — Company address

FAQ

Key Financial Figures

• $35.0 million — d Securities ("MVLS") was less than the $35.0 million minimum required for continued listing
• $2.5 million — Rules: stockholders' equity of at least $2.5 million or net income of $500,000 from continui
• $500,000 — at least $2.5 million or net income of $500,000 from continuing operations in the most

Filing Documents

• adap-20250911x8k.htm (8-K) — 36KB
• 0001104659-25-089558.txt ( ) — 148KB
• adap-20250911.xsd (EX-101.SCH) — 4KB
• adap-20250911_lab.xml (EX-101.LAB) — 16KB
• adap-20250911_pre.xml (EX-101.PRE) — 11KB
• adap-20250911x8k_htm.xml (XML) — 5KB

01

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 11, 2025, Adaptimmune Therapeutics plc (the "Company") received a written notice (the "Notice") from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that for the last 32 consecutive business days prior to the date of the Notice, the Company's Market Value of Listed Securities ("MVLS") was less than the $35.0 million minimum required for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(b)(2) (the "MVLS Listing Rule"). Additionally, as of the date of the Notice, the Company did not meet either of the alternative Nasdaq continued listing standards under the Nasdaq Listing Rules: stockholders' equity of at least $2.5 million or net income of $500,000 from continuing operations in the most recently completed fiscal year or in two of the three most recently completed fiscal years. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days, or until March 10, 2026, to regain compliance with the MVLS Listing Rule. In order to regain compliance with the MVLS Listing Rule, the Company's MVLS must meet or exceed $35.0 million for a minimum of ten consecutive business days during the 180-day compliance period after which the Staff will provide to the Company written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance with the MVLS Listing Rule during the 180-day compliance period, the Staff will provide the Company notice that the Company's securities will be subject to delisting, at which time, the Company may appeal the delisting determination to a Nasdaq hearings panel. The Notice has no immediate effect on the listing or trading of the Company's American Depositary Shares ("ADSs") on The Nasdaq Capital Market. However, if the Company fails to timely regain compl

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements that are not historical facts and can be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," or the negative of these terms, or other comparable terminology. These statements are based on our current expectations, estimates, and projections about our business and industry, management's beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements in this Current Report on Form 8-K include, but are not limited to, the Company's plans and ability to regain compliance with the MVLS Listing Rule and to maintain its listing on The Nasdaq Capital Market. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to the risks described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this current report on Form 8-K speak only as of the date the statements were made and the Company does not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. ADAPTIMMUNE THERAPEUTICS PLC Date:September 12, 2025 By: /s/ Margaret Henry Name: Margaret Henry Title: Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR